BiotechTube

ASP7991 + Cinacalcet + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism

Trial Timeline

Mar 14, 2014 → Nov 10, 2014

NCT ID
NCT02133404

About ASP7991 + Cinacalcet + Placebo

ASP7991 + Cinacalcet + Placebo is a phase 2 stage product being developed by Astellas Pharma for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02133404. Target conditions include Secondary Hyperparathyroidism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02133404Phase 2Completed

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
Cinacalcet HClKyowa KirinApproved
85
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
dirucotide + PlaceboEli LillyPhase 2/3
65
dirucotideEli LillyPhase 2/3
65
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
Birabresib Dose 20 mgMerckPhase 1
33
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
77
RanibizumabNovartisApproved
85
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
85
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85